Announcements Trials
Browse Landscape

Phase

Phase 4 8Phase NA 3Phase 3 2Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

beta-Thalassemia 1Neoplasms 1Hepatoblastoma 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Sugammadex × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡